Cargando…

Exploring drug-target interaction networks of illicit drugs

BACKGROUND: Drug addiction is a complex and chronic mental disease, which places a large burden on the American healthcare system due to its negative effects on patients and their families. Recently, network pharmacology is emerging as a promising approach to drug discovery by integrating network bi...

Descripción completa

Detalles Bibliográficos
Autores principales: Atreya, Ravi V, Sun, Jingchun, Zhao, Zhongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849475/
https://www.ncbi.nlm.nih.gov/pubmed/24268016
http://dx.doi.org/10.1186/1471-2164-14-S4-S1
_version_ 1782293932277760000
author Atreya, Ravi V
Sun, Jingchun
Zhao, Zhongming
author_facet Atreya, Ravi V
Sun, Jingchun
Zhao, Zhongming
author_sort Atreya, Ravi V
collection PubMed
description BACKGROUND: Drug addiction is a complex and chronic mental disease, which places a large burden on the American healthcare system due to its negative effects on patients and their families. Recently, network pharmacology is emerging as a promising approach to drug discovery by integrating network biology and polypharmacology, allowing for a deeper understanding of molecular mechanisms of drug actions at the systems level. This study seeks to apply this approach for investigation of illicit drugs and their targets in order to elucidate their interaction patterns and potential secondary drugs that can aid future research and clinical care. RESULTS: In this study, we extracted 188 illicit substances and their related information from the DrugBank database. The data process revealed 86 illicit drugs targeting a total of 73 unique human genes, which forms an illicit drug-target network. Compared to the full drug-target network from DrugBank, illicit drugs and their target genes tend to cluster together and form four subnetworks, corresponding to four major medication categories: depressants, stimulants, analgesics, and steroids. External analysis of Anatomical Therapeutic Chemical (ATC) second sublevel classifications confirmed that the illicit drugs have neurological functions or act via mechanisms of stimulants, opioids, and steroids. To further explore other drugs potentially having associations with illicit drugs, we constructed an illicit-extended drug-target network by adding the drugs that have the same target(s) as illicit drugs to the illicit drug-target network. After analyzing the degree and betweenness of the network, we identified hubs and bridge nodes, which might play important roles in the development and treatment of drug addiction. Among them, 49 non-illicit drugs might have potential to be used to treat addiction or have addictive effects, including some results that are supported by previous studies. CONCLUSIONS: This study presents the first systematic review of the network characteristics of illicit drugs, their targets, and other drugs that share the targets of these illicit drugs. The results, though preliminary, provide some novel insights into the molecular mechanisms of drug addiction. The observation of illicit-related drugs, with partial verification from previous studies, demonstrated that the network-assisted approach is promising for the identification of drug repositioning.
format Online
Article
Text
id pubmed-3849475
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38494752013-12-06 Exploring drug-target interaction networks of illicit drugs Atreya, Ravi V Sun, Jingchun Zhao, Zhongming BMC Genomics Research BACKGROUND: Drug addiction is a complex and chronic mental disease, which places a large burden on the American healthcare system due to its negative effects on patients and their families. Recently, network pharmacology is emerging as a promising approach to drug discovery by integrating network biology and polypharmacology, allowing for a deeper understanding of molecular mechanisms of drug actions at the systems level. This study seeks to apply this approach for investigation of illicit drugs and their targets in order to elucidate their interaction patterns and potential secondary drugs that can aid future research and clinical care. RESULTS: In this study, we extracted 188 illicit substances and their related information from the DrugBank database. The data process revealed 86 illicit drugs targeting a total of 73 unique human genes, which forms an illicit drug-target network. Compared to the full drug-target network from DrugBank, illicit drugs and their target genes tend to cluster together and form four subnetworks, corresponding to four major medication categories: depressants, stimulants, analgesics, and steroids. External analysis of Anatomical Therapeutic Chemical (ATC) second sublevel classifications confirmed that the illicit drugs have neurological functions or act via mechanisms of stimulants, opioids, and steroids. To further explore other drugs potentially having associations with illicit drugs, we constructed an illicit-extended drug-target network by adding the drugs that have the same target(s) as illicit drugs to the illicit drug-target network. After analyzing the degree and betweenness of the network, we identified hubs and bridge nodes, which might play important roles in the development and treatment of drug addiction. Among them, 49 non-illicit drugs might have potential to be used to treat addiction or have addictive effects, including some results that are supported by previous studies. CONCLUSIONS: This study presents the first systematic review of the network characteristics of illicit drugs, their targets, and other drugs that share the targets of these illicit drugs. The results, though preliminary, provide some novel insights into the molecular mechanisms of drug addiction. The observation of illicit-related drugs, with partial verification from previous studies, demonstrated that the network-assisted approach is promising for the identification of drug repositioning. BioMed Central 2013-10-01 /pmc/articles/PMC3849475/ /pubmed/24268016 http://dx.doi.org/10.1186/1471-2164-14-S4-S1 Text en Copyright © 2013 Atreya et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Atreya, Ravi V
Sun, Jingchun
Zhao, Zhongming
Exploring drug-target interaction networks of illicit drugs
title Exploring drug-target interaction networks of illicit drugs
title_full Exploring drug-target interaction networks of illicit drugs
title_fullStr Exploring drug-target interaction networks of illicit drugs
title_full_unstemmed Exploring drug-target interaction networks of illicit drugs
title_short Exploring drug-target interaction networks of illicit drugs
title_sort exploring drug-target interaction networks of illicit drugs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849475/
https://www.ncbi.nlm.nih.gov/pubmed/24268016
http://dx.doi.org/10.1186/1471-2164-14-S4-S1
work_keys_str_mv AT atreyaraviv exploringdrugtargetinteractionnetworksofillicitdrugs
AT sunjingchun exploringdrugtargetinteractionnetworksofillicitdrugs
AT zhaozhongming exploringdrugtargetinteractionnetworksofillicitdrugs